Establishment Labs Holdings Inc. · NASDAQ:ESTA
Establishment Labs — 39th Annual J.P. Morgan Healthcare Conference (January 2021)
19 slides from Establishment Labs's conference presentation, January 2021
Slide 1: Establishment Labs Holdings Inc. (NASDAQ: ESTA)
Establishment Labs Holdings Inc. (NASDAQ: ESTA) Juan José Chacón-Quirós – CEO & Founder JANUARY 2021
Slide 2: Safe Harbor and Forward Looking Statements
PROPRIETARY INFORMATION OF ESTABLISHMENT LABS HOLDINGS INC. (“Establishment Labs”) Safe Harbor The information contained in this document is Establishment Labs’ PROPRIETARY INFORMATION and is disclosed in CONFIDENCE. It is the property of Establishment Labs and and shall not be used, disclosed to ot
Slide 3: Reinventing Breast Aesthetics and Reconstruction
Reinventing Breast Aesthetics and Reconstruction
Slide 4: Breast Aesthetics Market Dynamics
Breast Aesthetics Market Dynamics • Relatively little innovation in implant technology • Products sold today date back to 1990s and earlier • Large competitors focused on other segments • Breast augmentation remains the #1 aesthetic surgical procedure, with 1.5 million performed annually 4
Slide 5: The Motiva Difference
The Motiva Difference ® • Unique surface technology demonstrates positive clinical ESTA offers the outcomes world’s most • Proprietary silicone gel family offers natural tactile feel comprehensive and movement portfolio of • High durability silicone shell advanced smooth • New features enhance produ
Slide 6: Lack of Innovation in the Breast Implant Industry
Lack of Innovation in the Breast Implant Industry Each of these prospective studies was conducted at multiple sites in the United States and Results from all surgery Sientra Allergan Mentor submitted by each of these companies as their core study supporting approval, as that cohorts 5-Year 6-Year 6-
Slide 7: Motiva Implants Clinical Complications Map
Motiva Implants Clinical Complications Map ® 1. Huemer et al. PRS, 2018 5. Rigo. APS, 2020 9. Data Complaint Report PMS. Q3, 2020 12. Giovanni Botti (up to 6 years) 2. D’Onofrio. APS, 2020 6. Chacón et al. ASJ, 2018 10. MotivaImagine APP Registered Patients 13. Charles Randquist (up to 5 years) 3. Y
Slide 8: Preliminary 3-Year Evaluation of SilkSurface and VelvetSurface Motiva Silicone Breast Implants
Preliminary 3-Year Evaluation of Experience with SilkSurface and VelvetSurface Motiva Silicone Breast Implants: A Single-Center Experience with 5,813 Consecutive Breast Augmentation Cases Aesthetic Surgery Journal. September 2017. Level of Evidence: 3 This retrospective study comprises 5,813 patient
Slide 9: Motiva's Unique Surface Demonstrates Positive Clinical Outcomes
Motiva’s Unique Surface Demonstrates Positive Clinical Outcomes 9
Slide 10: What Makes SmoothSilk/SilkSurface Unique?
What Makes SmoothSilk /SilkSurface Unique? ® ® Optimal Immune System Response (7) Doloff J. Overcoming host rejection response to improve breast implant biocompatibility. 15 Sep 2017. 3rd World Symposium on Ergonomic Implants, Lago di Garda. 10
Slide 11: How We Drive Growth
Establishment Labs How We Drive Growth Entering Expanding Launching new our direct new and markets sales model innovative products
Slide 12: Strong Financial Performance
Strong Financial Performance Revenue Gross Profit Margin $ in millions $89.6 $84.2-$85.2* 61% $61.2 59% 51% $34.7 2017 2018 2019 2020 2017 2018 2019 Q1 Q2 Q3 Q4 Column1 * Preliminary & unaudited FY 2020 estimate. Final results to be announced in March 2021. 12
Slide 13: Approvals in China and the U.S. Would Triple Addressable Market Opportunity
Approvals in China and the U.S. Would Triple Addressable Market Opportunity China United States • ~$150-$200M* market • ~½ of the global market and growing rapidly • ~80% of market is • Third largest affluent aesthetic procedures population globally Currently Addressable Future • Enrollment in aesth
Slide 14: New Products Represent Opportunities for Additional Growth
New Products Represent Opportunities for Additional Growth • Motiva Flora unlocks the breast reconstruction segment The only tissue expander for use alongside MRI scanning Broad commercial launch in Europe in early 2021 • Motiva Ergonomix2 can extend market share gains The next-generation of b
Slide 15: The Motiva Flora Tissue Expander Improves the Standard of Care in Breast Reconstruction
The Motiva Flora Tissue Expander Improves the Standard of Care in Breast Reconstruction • Integrated RFID port with no magnets • SmoothSilk® surface technology • Superior arch and orientation guides • Anatomical TrueFixation® system Not for sale in the U.S. 15
Slide 16: Motiva Ergonomix2 Improves Upon our Best-Selling Implant
Motiva Ergonomix2 Improves Upon our Best-Selling Implant • Features new Super Silicone™ technology The most advanced ultra-high purity chemistries for enhanced mechanical properties and improved ergonomics • Includes patented SmoothSilk surface technology ® • Available in wide range of sizes and p
Slide 17: Motiva Mia – A Disruptive Technology
Motiva Mia – A Disruptive Technology • Designed for women seeking a one-cup size up augmentation in a simple, minimally invasive procedure • Annually, as many as 1.9 million* women would consider a minimally invasive procedure • Offers augmentation considerably more subtle in sizing and approach N
Slide 18: Motiva Mia – Latest Developments
Motiva Mia – Latest Developments • Ergonomix2 Diamond implant received mark • IRB patient series in Costa Rica recently completed Approval included Motiva Ergonomix2 implant and proprietary tools 30 procedures performed in December • Positive reaction from plastic surgeons performing cases “Mia
Slide 19: Committed to women's health and well-being
Committed to women’s health and well-being establishmentlabs.com
Establishment Labs Holdings — 39th Annual J.P. Morgan Healthcare Conference (January 2021) on 6ix